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ABSTRACT 
Background: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, 
metabolic activity and patient outcome. This study aimed to evaluate the biological and 
prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the 
intrinsic molecular subtypes. 
Methods: SLC3A2 was assessed at the genomic level, using METABRIC data (n=1,980), 
and proteomic level, using immunohistochemistry on TMA sections constructed from a large 
well-characterised primary BC cohort (n=2,500). SLC3A2 expression was correlated with 
clinicopathological parameters, molecular subtypes, and patient outcome. 
Results: SLC3A2 mRNA and protein expression were strongly correlated with higher tumour 
grade and poor Nottingham prognostic index (NPI). High expression of SLC3A2 was 
observed in triple negative (TN), HER2+, and ER+ high proliferation subtypes. SLC3A2 
mRNA and protein expression were significantly associated with the expression of c-MYC in 
all BC subtypes (p<0.001). High expression of SLC3A2 protein was associated with poor 
patient outcome (p<0.001)), but only in the ER+ high proliferation (p=0.01) and triple 
negative (p=0.04) subtypes. In multivariate analysis SLC3A2 protein was an independent risk 
factor for shorter breast cancer specific survival (p<0.001). 
Conclusions: SLC3A2 appears to play a role in the aggressive BC subtypes driven by MYC 
and could act as a potential prognostic marker. Functional assessment is necessary to reveal 
its potential therapeutic value in the different BC subtypes. 
Running title: SLC3A2 in molecular subtypes of breast cancer. 
Key words: SLC3A2, breast cancer, prognosis. 
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INTRODUCTION 
Metabolic reprogramming has been readily accepted as part of the revised hallmarks of cancer 
where tumour cells are able to modulate their metabolic pathways to support their unremitting 
proliferation (Hanahan, 2011). Amino acid transport systems are essential for the growth of 
cancer cells, not only because they provide amino acids required for protein synthesis, but also, 
they activate mammalian target of rapamycin complex 1 (mTORC1) which in turn regulates 
protein translation and cell growth (Bar-Peled & Sabatini, 2014; Bond, 2016). There is also 
growing evidence that cross-talk can occur among oncogenes and/or tumour suppressor genes 
and altering the cancer cell metabolism, including the direct regulation of the Solute carrier 
family 3 member 2 (SLC3A2) by the oncogene MYC (Kim et al, 2008). 
Recently, membrane transporters have attracted great attention for their crucial roles in cancer 
proliferation and survival. SLC3A2, also known as CD98hc, is a trans-membrane protein which 
primarily acts as a chaperone that heterodimerises with a group of amino acid transporters (e.g. 
SLC7A5 and SLC7A11) for their functional expression in the plasma membrane (Fotiadis et al, 
2013; Kanai et al, 1998). SLC3A2 also has a biological role in favouring cancer growth, as it 
associates and regulates the function of β1 integrins (ITGB1) and its overexpression leads to 
amplification of integrin-dependent signals which involves extracellular matrix remodelling 
resulting in promoting tumorigenesis and cell proliferation (Levental et al, 2009; Prager et al, 
2007). 
SLC3A2 is highly expressed in various cancer types including gastric cancer(Yang et al, 2012), 
osteosarcoma (Zhu et al, 2017), renal cell carcinoma (Prager et al, 2009) and biliary tract cancer 
(Kaira et al, 2014). Previous studies of SLC3A2 in human BC showed its prognostic 
significance but in a limited number of cases (Esseghir et al, 2006; Furuya et al, 2012). To our 
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knowledge there is no prognostic analysis which involves the impact of SLC3A2 
overexpression in large cohorts including the different BC molecular subtypes. 
In this study, we aimed to assess SLC3A2 gene copy number and mRNA expression alongside 
protein expression in large and well-characterised annotated cohorts of BC to determine its 
clinicopathological and prognostic value with emphasis on the different molecular classes. 
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MATERIAL AND METHODS 
SLC3A2 genomic profiling 
A cohort of 1,980 invasive BC in the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) (Curtis et al, 2012) was used to evaluate SLC3A2 gene copy number 
aberrations and gene expression. In the METABRIC study, DNA/RNA was isolated from fresh 
frozen samples and transcriptional profiling was obtained using the Illumina HT-12v3 
platforms. Data was pre-processed and normalised as described previously (Curtis et al, 2012). 
In this cohort, patients who were oestrogen receptor-positive (ER+) and /or Lymph Node (LN)-
negative did not receive adjuvant chemotherapy, whereas ER- and LN+ patients were offered 
adjuvant chemotherapy. None of the patients were treated with anti-HER2 targeted therapy. 
Dichotomisation of SLC3A2 mRNA expression was determined using the median value as the 
cut-off point. The association between the SLC3A2 mRNA expression and clinicopathological 
parameters, molecular subtypes, and patient outcome was investigated. 
The online dataset, Breast Cancer Gene Expression Miner v4.0 
(http://bcgenex.centregauducheau.fr), was used for external validation of SLC3A2 mRNA 
expression. 
SLC3A2 protein expression 
Immunhisotchemistry for SLC3A2 was performed using a well-characterised cohort of early 
stage primary operable invasive BC patients aged ≤ 70 years. Patients presented at Nottingham 
City Hospital between 1989 and 2006. Patients were managed based on a uniform protocol. 
Clinical history, tumour characteristics, information on therapy and outcomes are 
prospectively maintained. Outcome data included development and time to distant metastasis 
(DM) and breast cancer specific survival (BCSS). 
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The clinicopathological parameters for the Nottingham and METABRIC series are 
summarised in (Supplementary Table 1). 
Western blotting 
The antibody specificity of anti-SLC3A2 (HPA017980, Sigma-Aldrich, UK) was validated 
using Western blotting in MDA-MB-231 BC lysate (American Type Culture Collection; 
Rockville, MD, USA) as previously described (Craze et al, 2017). A single band for SLC3A2 
was visualised at the correct predicted size (80 KDa) (Figure 2A). 
Tissue arrays and Immunohistochemistry 
Tumour samples, 0.6mm cores, were arrayed as previously described (Abd El-Rehim et al, 
2005). Immunohistochemical staining was performed on 4 μm TMA sections using Novolink 
polymer detection system (Leica Biosystems, RE7150-K) as previously described (Craze et 
al, 2017). 
Stained TMA sections were scanned using high resolution digital images (NanoZoomer; 
Hamamatsu Photonics, Welwyn Garden City, UK), at x20 magnification. Evaluation of 
staining for SLC3A2 was based on a semi-quantitative assessment of cores’ digital images 
using a modified histochemical score (H-score) which includes an assessment of both the 
intensity and the percentage of stained cells (McCarty & McCarty, 1984). Staining intensity 
was assessed as follows 0, negative; 1, weak; 2, medium; 3, strong and the percentage of the 
positively stained tumour cells was estimated subjectively. The final H-score was calculated 
multiplying the percentage of positive cells (0-100) by the intensity (0-3), producing a total 
range of 0-300. Dichotomisation of protein expression was determined using the median 
value as the cut-off point. 
Immunhistochemical staining and dichotomisation of the other biomarkers included in this 
study were as per previous publications (Abd El-Rehim et al, 2005; Abdel-Fatah et al, 2010; 
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Aleskandarany et al, 2011a; Aleskandarany et al, 2010; Aleskandarany et al, 2011b; Elsheikh 
et al, 2008; Green et al, 2016; Green et al, 2015; Jerjees et al, 2015; Lancashire et al, 2010) 
(Supplementary table 2). ER and PgR positivity was defined as ≥1% staining. 
Immunoreactivity of HER2 was scored using standard HercepTest guidelines (Dako). 
Chromogenic in situ Hybridisation (CISH) was used to quantify HER2 gene amplification in 
borderline cases using the HER2 FISH pharmDxTM plus HER2 CISH pharmDxTM kit (Dako) 
and was assessed according to the American Society of Clinical Oncology guidelines. BC 
molecular subtypes were defined, based on tumour IHC profile and the Elston-Ellis (Elston & 
Ellis, 2002) mitotic score as: ER+/HER2- Low Proliferation (mitotic score 1), ER+/HER2-
High Proliferation (mitotic score 2 and 3), HER2-positive class: HER2+ regardless of ER 
status, Triple Negative (TN): ER-, PgR- and HER2- (Senkus et al, 2015). 
Statistical analysis 
Statistical analysis was performed using SPSS 22.0 statistical software (SPSS Inc., Chicago, 
IL, USA). Spearman’s correlation coefficient was carried out to examine the association 
between continuous variables. The Chi-square test was performed for inter-relationships 
between categorical variables. Survival curves were analysed by Kaplan-Meier with Log 
Rank test using breast cancer specific death censoring cases who were lost to follow up or 
died of other causes. Cox’s proportional hazard method was performed for multivariate 
analysis to identify the independent prognostic/predictive factors and the proportional hazard 
assumption was tested with Schoenfeld residuals test to avoid violation of the assumption The 
statistical test for heterogeneity was applied to assess the difference between the subtypes. P-
values were adjusted using Bonferroni correction for multiple testing, whenever applicable. A 
p-value ˂0.05 was considered significant. The study endpoints were 5-year BCSS or distant 
metastasis free survival (DMFS). 
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This study was approved by the Nottingham Research Ethics Committee 2 under the title 
‘Development of a molecular genetic classification of breast cancer’. 
RESULTS 
SLC3A2 genomic profiling in BC 
High SLC3A2 mRNA expression was observed in 961/1,858 (52%) of the METABRIC BC 
cases. 90 (4.5%) of cases showed SLC3A2 copy number (CN) gain whereas 109 (5.5%) showed 
a CN loss. A significant association was observed between SLC3A2 copy number variation 
(CNV) and SLC3A2 mRNA expression (p<0.001, Figure 1A). There was a positive association 
between SLC3A2 CN gain and its regulator, MYC, gain (p<0.001, Supplementary Table 2). 
High SLC3A2 mRNA expression was significantly associated with higher tumour grade (Figure 
1B, p<0.001), positive nodal metastasis (Figure 1C, p<0.001) and poor Nottingham Prognostic 
Index (NPI) (Figure 1D, p<0.001). These associations were confirmed using the Breast Cancer 
Gene-Expression Miner v4.0 (Supplementary Figure 1A, 1B). 
The correlation of SLC3A2 mRNA with other relevant genes were investigated using the 
METABRIC dataset (Supplementary Table 4). The genes were selected based on previous 
publications, being either regulatory genes or those that share or support the SLC3A2 
biological function focussing primarily on the amino acid transport system. There was a 
relationship between SLC3A2 and the regulatory genes, ATF4 (p= 0.02) and MYC with the latter 
showing significant correlation across all BC subtypes (p<0.001). High SLC3A2 mRNA 
expression was significantly associated with its heterodimers, the glutamine exchanger, SLC7A5 
and, the glutamate transporter, SLC7A11 (all p=0.002). Nevertheless, the majority of other 
glutamine transporters were negatively correlated with the SLC3A2 expression. A similar 
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association was also observed with glutaminase (GLS) enzyme, which mediates the 
conversion of glutamine to glutamate (p<0.001). High SLC3A2 mRNA expression was 
associated with those tumours where there were TP53 mutations (p<0.001, Table 2). 
SLC3A2 protein expression in BC 
SLC3A2 protein expression was observed, predominantly in the membrane of invasive BC 
cells, with expression levels varying from absent to high (Figure 2B and 2C). Positive 
SLC3A2 protein expression (> 15 H-score) was observed in 50% of the cases. 
Table 1 summarises the observed associations with high SLC3A2 protein expression 
including larger tumour size (p=0.006), high tumour grade (p<0.001), and poor NPI 
(p<0.001). In addition, high SLC3A2 protein was associated with medullary-like tumours 
(p<0.001). Regarding BC metastatic sites, high SLC3A2 protein levels were associated with 
the development of distant metastases to the brain (p<0.001) while there was no association 
with developing DM to the bone or lung. 
SLC3A2 protein was significantly expressed with high Ki67 and c-MYC expression (p<0.001, 
Supplementary Table 5). SLC7A5, SLC1A5, GLS, and PIK3CA were significantly expressed 
in breast tumours with high expression of SLC3A2 (p<0.001), while the low expression was 
associated with high levels of p-mTORC1 (p<0.001, Supplementary Table 5). Moreover, high 
SLC3A2 protein was positively associated with high nuclear p53 protein expression (p<0.001, 
Table 2). 
SLC3A2 expression in molecular BC intrinsic subtypes 
High expression of SLC3A2 mRNA was significantly associated with hormone receptor 
negative (ER- and PR-) tumours (p≤0.001, Table 2) but not with HER2+ BC. These results 
were in concordance with the Breast Cancer Gene-Expression Miner v4.0 (Supplementary 
Figure 1C-F). Similarly, SLC3A2 protein expression was associated with negative hormone 
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status and HER2+ tumours (all p≤0.001, Table 2) and it was highly expressed in TN 
compared with non-TN tumours (p<0.001, Table 2). 
When comparing the levels of SLC3A2 CN and mRNA expression in the intrinsic (PAM50) 
subtype (Parker et al, 2009), high mRNA expression was observed in Basal-like, Luminal B 
and HER2+ tumours (Figure 1E, p<0.001) whereas SLC3A2 CN gain was primarily observed 
in Luminal B subtype and to lesser extent in HER2+ and TNBC (p<0.001, Supplementary 
Table 3). In the METABRIC Integrative Clusters, high SLC3A2 mRNA expression was 
associated with clusters 1 (Luminal B subgroup), 5 (ERBB2 amplified) and 10 (TN/basal-
like) with proportions 63%, 61% and 65% respectively (p<0.001, Figure 1F). Association of 
SLC3A2 mRNA with the molecular subtypes was confirmed using the Breast Cancer Gene-
Expression Miner v4.0 (Supplementary Figure 1G). 
Expression of SLC3A2 protein in the defined molecular subtypes showed a lower expression 
in the ER+ low proliferation tumours compared with the other subtypes (p<0.001, Table 1). 
SLC3A2 expression and patient outcome 
High SLC3A2 protein expression, but not mRNA, was associated with poor outcome in terms 
of shorter BCSS (p<0.001, Figure 3A-B ). When investigating within the molecular classes, 
high expression of SLC3A2 protein was predictive of shorter BCSS in ER+ high proliferation 
class (p=0.01, Figure 3D), and TN tumours (p= 0.04, Figure 3F).There was no association 
between SLC3A2 protein and outcome in HER2+ (Figure 3E) and ER+ low proliferation 
tumours (Figure 3C). 
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High SLC3A2 protein expression was associated with shorter DMFS(p<0.001; Supplementary 
Figure 2A) and this was only observed in ER+ high proliferation and TN tumours (p=0.04, 
Supplementary Figure 2C, 2E) but not with other two subtypes (Supplementary Figure 2B, 
2D). 
In multivariate Cox regression analysis, SLC3A2 protein was a predictor of shorter BCSS 
(p<0.001, Table 3) independent of tumour size, grade, and stage. The same significant result 
was remained in the ER+ high proliferation and TN tumours (p=0.01, Supplementary table 6) 
when different subtypes where considered. However, Heterogeneity test revealed no evidence 
of a difference in the observed effects for the three aggressive subtypes, ER+ high 
proliferation, HER2+ and TN tumours, after adjusting the confounding variables (p=0.91 and 
p=0.90 in BCSS and DMFS) respectively (data not shown). 
DISCUSSION 
BC is a heterogeneous disease (Perou et al, 2000) and the high level of diversity among the 
various subtypes is reflected on the clinical behavior, response to therapy and patient 
outcome. In addition, different subtypes exhibit a disparity in their metabolic pathways and 
nutritional needs. ER+/luminal tumours are the most common BC subtypes (Dawson et al, 
2013; Rakha et al, 2007) which are also different it terms of disease prognosis and mortality 
rates (Dawson et al, 2013). 
Solute carrier (SLC) proteins are related to tumorigenesis and drug resistance in cancer cells 
(Januchowski et al, 2013) and SLC3A2 is characterised by its dual effect to promote cancer 
cell growth and survival. Beside its role in regulating the function of amino acid transporter 
systems, it modulates integrin-induced signal transduction which derives malignant tumour 
cells’ behavior including cell spreading and migration (Poettler et al, 2013). 
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The present study involved a large BC cohort to reveal the significant association between the 
high SLC3A2 protein expression and the poor prognostic clinico-pathological parameters. 
Furthermore, high SLC3A2 expression was significantly associated with proliferation. This 
supports the results of previous studies which reported that these, SLC3A2 and Ki67, are 
significantly correlated in non-small cell lung cancer (Kaira et al, 2010) and hypo-pharyngeal 
squamous cell carcinoma (Toyoda et al, 2015), confirming that SLC3A2 is critical for 
proliferation in cancer cells. 
Regarding the ER+ BC subtypes, SLC3A2 expression was lower in ER+ tumours that have 
low proliferation compared with the highly proliferative ER+ tumours, and it was associated 
with poor patient outcome in the latter class only. This is doubtlessly attributable to their 
aggressive character as well as their heavier nutrient requirements for cell survival and 
proliferation. 
SLC3A2 protein was also highly expressed in TNBC and HER2+, in concordance with Furuya 
et al (Furuya et al, 2012). However, the significant association between SLC3A2 protein 
expression and patient outcome was only restricted to TNBC. In this regard, it has been 
shown that over-expression of SLC3A2 is actively involved in the proliferation of vascular 
smooth muscle cells and is necessary for efficient angiogenesis (Fogelstrand et al, 2009; Liao 
& Cantor, 2016). In this study, ER+ high proliferation and TN tumours, showed the most 
significant positive correlation between the mRNA expression of SLC3A2 and Vascular 
Endothelial Growth Factor (VEGFB) which maintains the continuity of angiogenesis and thus 
implicated for the metastatic process (Zhang et al, 2009). Although the association between 
HER2+ tumours and patient outcome was not nominally significant, there was no difference 
in the effect of this subtype and the other aggressive tumour types. 
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Generally, the association with patient outcome was observed at the protein, but not the 
mRNA, level. This can be attributed to the post translational modification, N-glycosylation, of 
the SLC3A2 protein which is required to make this protein functioning as it is renowned that 
the glycosylated SLC3A2 (~ 80 kDa) is necessary to form the heterodimeric complex which 
further assist the amino acid transport function. 
Previous studies have showed regulation of SLC3A2 by other proteins including the tumour 
oncogene c-Myc (Kim et al, 2008). In the current study, the relationship between SLC3A2 
and other regulatory proteins in both mRNA and protein expression was investigated. A 
positive relationship was observed between SLC3A2 and c-Myc, at both protein and mRNA 
levels and this correlation was observed in all BC subtypes when tested at the mRNA level. 
However it was only significant with the ER+ high proliferation and TN tumours (p= 0.006 
and p= 0.002) respectively, when investigated at the protein level (data not shown). 
The heavy chain of SLC3A2 forms a disulfide bond with the light chain of a group of amino 
acid transporters mediating their functions in the plasma membrane. The most prominent is the 
glutamine exchanger (SLC7A5) which imports the essential amino acids to cancer cells in 
exchange for intracellular glutamine, the procedure which subsequently activates mTORC1 
(Bar-Peled & Sabatini, 2014; Bond, 2016). Another protein which heterodimerises with 
SLC3A2 is the cysteine-glutamate transporter (SLC7A11), which potentiates the cellular anti-
oxidant machinery through assisting the glutathione synthesis (Lo et al, 2008). This study 
revealed the depth of the positive correlation between these amino acid transporters, 
specifically for SLC7A5 which remained significant in almost all subtypes, apart from in 
luminal A tumours. Hence, we investigated the association of SLC3A2 with the downstream 
signal, mTORC1. However, high SLC3A2 protein expression was associated with lower 
expression of the mTORC1 phosphorylated at ser (2448), which was included in this study, 
and this attributed to what was confirmed by Cheng et al, that phosphorylation of mTORC1 at 
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ser (2448), which is stimulated by growth factors, was mutually exclusive with mTORC1 
phosphorylated at thr (2446), which is regulated by amino acids (Cheng et al, 2004). 
This study further investigated the association of SLC3A2 expression with other glutamine 
transporters which provide the substrate, glutamine, required to operate the SLC3A2-SLC7A5 
heterodimeric complex. Glutaminase (GLS), which converts glutamine to glutamate, is the 
substrate needed for SC3A2-SLC7A11 function. Although the mRNA showed a negative 
correlation with most glutamine transporters and GLS, the high SLC3A2 protein expression 
was associated with the higher levels of the glutamine transporter (SLC1A5), SLC7A5 and 
GLS, indicating a system of functional coupling between these biomarkers at the protein level. 
The role of the tumour microenvironment is well known with respect to disease development 
and progression, and SLC3A2 appears to have a role in this, as the SLC3A2 heavy chain binds 
to the cytoplasmic tail of integrin β1 which in turn mediates extracellular matrix remodeling 
that controls cell spreading, survival and growth (Fenczik et al, 1997; Feral et al, 2005). The 
SLC3A2 interaction with integrin is well studied in renal cancer cell (Poettler et al, 2013) and 
the current study also confirmed the positive correlation between gene expressions in all BC 
subtypes. 
A recent study reported that SLC3A2 influences osteosarcoma growth through the PI3K/AKt 
signaling pathway (Zhu et al, 2017) and this could be the case in BC as demonstrated by our 
finding that high levels of SLC3A2 protein is positively associated with PIK3CA expression. 
Therefore, it appears that all functions of SLC3A2 in BC were associated with poor prognosis 
and would not be in favour of patients with aggressive subtypes. 
Targeting SLC3A2 efficiently decreases colony formation of osteosarcoma cells (Zhu et al, 
2017) and affects renal cancer cell growth in vivo (Poettler et al, 2013). The consequences of 
blocking SLC3A2 is therefore warranted in the aggressive highly proliferative BC subtypes. 
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Conclusion 
This study revealed that SLC3A2 was associated with poor prognostic characteristics and 
poor survival outcome. Over-expression of SLC3A2 appears to play a role in the proliferation 
and progression of the highly proliferative ER+, HER2+ and TN subtypes of BC, thus it could 
act as a potential prognostic marker and therapeutic target. Functional assessment is necessary 
to reveal the specific role played by this membrane protein in the highly proliferative more 
aggressive BC subclasses. 
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Low High χ2 Adjusted
n (%) n (%) (p-value) p-value
≥ 2.0cm 526 (47.7) 576 (52.3) 7.49
˂ 2.0cm 736 (53.3) 646 (46.7) (0.006) 0.03
1 252 (62.7) 150 (37.3)
2 543 (56.9) 412 (43.1) 76.34
3 466 (41.4) 659 (58.6) (2.6x10
-17) <0.0001
1 794 (51.2) 756 (48.8)
2 350 (50.1) 349 (49.9) 0.292
3 115 (50.2) 114 (49.8) (0.86) 1.72
Good 481 (58.9) 337 (41.1)
Moderate 611 (48.2) 657 (51.8) 36.37
Poor 167 (42.5) 226 (57.5) (8.01x10
-7) <0.0001
ER+/HER2- Low Proliferation 748 (58.0) 542 (42.0)
ER+/HER2- High Proliferation 156 (42.9 208 (57.1) 66.58
Triple Negative 153 (39.5) 234 (60.5) (2.3x10
-14) <0.0001
Histological type
Ductal (including mixed) 1039 (49.5) 1060 (50.5)
Lobular 141 (62.7) 84 (37.3)
Medullary 9 (25.7) 26 (74.3) 29.73
Miscellanous 9 (50.0) 9 (50.0) (0.0002) 0.001
Special type 59 (57.3) 44 (42.7)
HER2+ 94 (38.4) 151 (61.6)
Site of distant metastasis
Brain
No 648 (72.6) 245 (27.4) 17.08
Yes 25 (46.3) 29 (53.7) (0.00003) 0.0002
Viscera
No 649 (70.4) 273 (29.6) 5.065
Yes 26 (89.7) 3 (10.3) (0.02) 0.1
Bone
No 529 (70.9) 217 (29.1) 0.041
Yes 144 (71.6) 57 (28.4) (0.839) 2.51
Lung
No 618 (71.7) 244 (28.3) 1.837
Yes 55 (64.7) 30 (35.3) (0.175) 0.7
IHC Subtypes 
Nottingham Prognostic Index (NPI)
Table 1. Clinicopathological associations of SLC3A2 expression in breast cancer
Tumour size 
Tumour Grade
   SLC3A2 protein
Lymph Node Stage
Low High χ2 Adjusted Low High χ2 Adjusted
n (%) n (%) (p-value) p-value n (%) n (%) (p-value) p-value
Negative 182 (40.1) 272 (59.9) 16.138 208 (38.1) 338 (61.9) 44.97
Positive 715 (50.9) 689 (49.1) (0.0003) 0.0009 1051 (54.3) 883 (45.7) (1.9x10
-11
) <0.0001
Negative 390 (43.6) 504 (56.4) 14.943 708 (46.4) 818 (53.6) 28.5
Positive 507 (52.6) 457 (47.4) (0.001) 0.002 466 (58.0) 337 (42.0) (9.3x10
-8
) <0.0001
Negative 799 (49.2) 826 (50.8) 4.125 1090 (51.9) 1009 (48.1) 16.14
Positive 98 (42.1) 135 (59.9) (0.04) 0.08 94 (38.4) 151 (61.6) (0.00005) <0.0001
No 786 (50.7) 765 (49.3) 21.64 1082 (53.0) 961 (47.0) 23.61
Yes 111(36.2) 196 (63.8) (0.000003) <0.0001 156 (39.6) 238 (60.4) (0.000001) 0.0001
Wild-type 280 (42.1) 385 (57.9) 37.41
Mutation 27 (28.7) 67 (71.3) (3.7x10
-8
) <0.0001
Negative 499 (76.7) 152 (23.3) 40.299
Positive 146 (55.5) 269 (29.4) (2.1x10
-10
 ) <0.0001
N/A
Triple Negative
SLC3A2 (mRNA)
TP53 mutations
p53 protein
                              N/A
                       SLC3A2 (Protein)
ER
PR
HER2
Hazard ratio p-value Hazard ratio p-value
(95% CI) (95% CI)
SLC3A2 Low vs.  high 2.17 (1.69-2.79) 1.4x10
-9 1.83 (1.42-2.36) 0.000003
Size <2cm vs.  ≥2cm 2.89 (2.37-3.53) 1.1x10
-25 1.55 (1.19-2.01) 0.001
Grade G1 vs.  G2&3 4.39 (3.55-5.43) 2.5x10
-42 4.04 (3.00-5.43) 2.8x10
-20
Lymph node Stage N1 vs.  N2&3 2.49 (2.21-2.81) 2.2x10
-50 2.11 (1.81-2.47) 4.5x10
-21
Table 3: Univariate and multivariate analysis of prognostic variables and SLC3A2 expression in relation to BCSS
Univariate Multivariate
SLC3A2 protein
Variable
Table 3: Univariate and multivariate analysis of prognostic variables and SLC3A2 expression in relation to BCSS
P=0.703
P<0.0001
P<0.0001
P<0.0001
P<0.0001
P=0.368
F= 10.308, p= 1.1x10-15F= 16.656, p= 1.9x10-13
A B
D E F
P<0.0001
P<0.0001
P=0.58
P<0.0001
P<0.0001
P<0.0001
C
AB C
SLC3A2
β-Actin
MDA-MB-
231
36          
55          
72          
95          
n= 1119
n= 1070
LogRank= 38.56, p= 5.2x10-10
n= 654
n= 473
LogRank= 0.53, p=0.46
ER+ Low proliferation
n= 141
n= 175
LogRank= 6.13, p= 0.01
ER+ High proliferation
n= 84
n= 136
HER2+
LogRank= 1.65, p= 0.19
n= 142
n= 209
Triple Negative
LogRank= 4.10, p= 0.04
A B C
D E F
n= 773
n= 802
LogRank= 0.32, p=0.57
A
B C
D E F G
n= 1246
n= 1205
n=538
n= 739 n= 154
n= 205
n= 93
n= 146
n= 151
n= 228
LogRank= 0.62, p= 0.43LogRank= 26.26, p= 2.9x10
-7
ER+ Low proliferation ER+ High proliferation
HER2+
Triple Negative
LogRank= 2.11, p= 0.15 LogRank= 4.18, p= 0.04
LogRank= 3.99, p= 0.04
A B C
D E
Supplementary Table 1. Clinicopathological parameters of the METABRIC and 
Nottingham breast cancer series. 
 METABRIC 
series  
n (%) 
Nottingham 
TMA series 
n (%) 
Age   
≥ 50 years 1426 (78.6) 1784 (67.4) 
˂ 50 years 424 (21.4) 864 (32.6) 
Tumour size   
≥ 2cm 1337 (68.2) 1176 (44.4) 
˂2cm 623 (31.8) 1471 (55.6) 
Grade   
1 169 (9.0) 421 (15.9) 
2 770 (40.7) 988 (37.4) 
3 952 (50.3) 1235 (46.7) 
Tumour type   
Ductal (including 
mixed) 
1545 (83.6) 2257 (85.3) 
Lobular 148 (8.0) 221 (8.4) 
Medullary-like 32 (1.7) 39 (1.5) 
Miscellaneous 12 (0.6) 16 (0.6) 
Special type 113 (6.1) 113 (4.2) 
Vascular Invasion   
Definite Not available 833 (31.5) 
Negative/Probable 
 
1808 (68.5) 
Lymph Node Stage 
1 1035 (52.5) 674 (61.0) 
2 623 (31.5) 341 (30.8) 
3 315 (16.0) 91   (8.2) 
Follow-up Status   
Alive     1070 (55.7) 1679 (63.4) 
Died from Breast 
Cancer 
505 (26.3) 647 (24.4) 
Died from other 
causes 
345 (18.0) 321 (12.2) 
ER   
Negative 472 (23.8)   570 (21.6) 
Positive 1508 (76.2) 2067 (78.4) 
PgR   
Negative 938 (47.4) 1047 (41.4) 
Positive 1042 (52.6) 1483 (58.6) 
HER2   
Negative 1734 (87.5) 2297 (88.5) 
Positive 246 (12.5) 298(11.5) 
 
  
Supplementary Table 2: Biomarkers - cut-offs used in the study 
 
 
  
Marker Cut-off 
ER ≥1% 
PgR ≥1% 
HER2 3+ and 2+ with amplification 
Ki67 ≥10% 
c-MYC >35 H-score 
p53 >10% 
PIK3CA >100 H-score 
p-mTORC1 >35 H-score 
GLS >120 H-score 
SLC1A5 >45 H-score 
SLC7A5 >15 H-score 
Supplementary Table 3: Copy Number Aberrations of SLC3A2 in breast cancer and their associations 
with MYC and molecular subtypes 
 
            SLC3A2 Gain 
 No Yes χ2 (p-value) 
MYC Gain    
No 1205(97.0) 37 (3.0) 18.843 
(0.00001) Yes 685 (92.8) 53 (7.2) 
Molecular subtypes    
Luminal A 703 (97.9) 15 (2.1)  
30.912 
(0.000003) 
Luminal B 445 (91.2) 43(8.8) 
Basal 315 (95.7) 14 (4.3) 
HER2 229 (95.4) 11 (4.6) 
Normal-like 1884 (95.4) 7 (3.5) 
 
Supplementary Table 4: Correlation of SLC3A2 mRNA expression with the expression of other 
genes 
 SLC3A2 mRNA 
       All cases 
     (n=1,980) 
    Luminal A 
  (n=368) 
Luminal B 
 (n=367) 
HER2+ 
(n=110) 
Triple negative 
(n=150) 
                                                          Correlation Coefficient  
                                                         (p-value) 
Adjusted p-value 
Regulatory and other associated genes 
MYC 0.390  
(4.7x10-73) 
<0.0001 0.388  
(3.1x10-27) 
<0.0001 0.348  
(2.4x10-15) 
<0.0001 0.502  
(1.04x10-16) 
<0.0001 0.301  
(2.5x10-8) 
<0.0001 
mTOR -0.272  
(5.2x10-35) 
<0.0001 -0.326  
(2.7x10-19) 
<0.0001 -0.128  
(0.005) 
0.07 -0.221  
(0.001) 
0.01 -0.349  
(7.0x10-11) 
<0.0001 
VEGFB 0.149  
(2.8x10-11) 
<0.0001 0.129  
(0.001) 
0.01 0.213  
(0.000002) 
<0.0001 0.134  
(0.03) 
0.27 0.310  
(9.2x10-9) 
<0.0001 
ITGB1 0.459  
(1.3x10-103) 
<0.0001 0.458  
(1.7x10-38) 
<0.0001 0.314  
(1.3x10-12) 
<0.0001 0.676  
(1.9x10-33) 
<0.0001 0.443  
(3.2x10-17) 
<0.0001 
ATF4 0.065 
 (0.004) 
0.02 -0.018 
 (0.626) 
2.50 -0.016  
(0.720) 
4.32 0.160  
(0.102) 
0.714 0.169 
(0.002) 
0.02 
Glutamine metabolism 
GLS -0.127  
(1.4x10-8) 
<0.0001 -0.150  
(0.00005) 
0.0006 -0.041  
(0.365) 
3.228 0.160  
(0.01) 
0.10 0.164 
(0.003) 
0.03 
Glutamine/Glutamate transporters 
SLC7A5 0.172  
(1.1x10-14) 
<0.0001 0.067  
(0.072) 
0.49 0.193  
(0.00001) 
0.0002 0.184  
(0.004) 
0.04 0.158  
(0.004) 
0.04 
SLC7A11 0.081  
(0.0003) 
0.002 0.031  
(0.409) 
2.04 0.107  
(0.01) 
0.14 0.036  
(0.574) 
1.72 0.138  
(0.01) 
0.10 
SLC1A5 -0.098  
(0.00001) 
0.0001 -0.153  
(0.00003) 
0.0004 -0.054  
(0.236) 
2.36 -0.228  
(0.0003) 
0.004 -0.135  
(0.016) 
0.08 
SLC6A19 0.041  
(0.07) 
0.28 0.073  
(0.051) 
0.40 0.002  
(0.967) 
2.90 0.022  
(0.732) 
1.46 0.123  
(0.025) 
0.14 
SLC7A6 -0.211  
(2.1x10-21) 
<0.0001 -0.285  
(7.1x10-15) 
<0.0001 -0.097  
(0.03) 
0.39 -0.339  
(7.0x10-8) 
<0.0001 -0.320  
(2.9x10-9) 
<0.0001 
SLC7A7 0.191  
(1.1x10-17) 
<0.0001 0.196  
(1.2x10-7) 
<0.0001 0.081  
(0.075) 
0.84 0.235  
(0.0002) 
0.003 0.137  
(0.01) 
0.09 
SLC7A8 -0.078 
 (0.001) 
0.005 -0.004  
(0.915) 
1.83 0.072  
(0.110) 
1.21 -0.194  
(0.003) 
0.03 -0.072  
(0.194) 
0.78 
SLC7A9 -0.155  
(3.9x10-12) 
<0.0001 -0.186  
(4.8x10-7) 
<0.0001 -0.037  
(0.410) 
3.28 -0.197 
 (0.002) 
0.02 -0.103  
(0.063) 
0.36 
SLC38A1 -0.101 
 (0.000006) 
0.0001 -0.080 
 (0.03) 
0.27 0.001  
(0.978) 
1.95 -0.037  
(0.568) 
2.27 -0.222  
(0.00004) 
0.0006 
SLC38A2 -0.223  
(7.7x10-24) 
<0.0001 -0.231  
(3.9x10-10) 
<0.0001 -0.188 
 (0.00002) 
0.0003 -0.283  
(0.000009) 
0.0002 -0.199  
(0.0002) 
0.002 
SLC38A3 -0.064  
(0.004) 
0.02 -0.114  
(0.002) 
0.02 -0.033  
(0.464) 
3.24 -0.113  
(0.08) 
0.64 -0.082  
(0.139) 
0.69 
SLC38A5 -0.016  
(0.472) 
0.94 -0.016  
(0.673) 
2.02 0.004  
(0.933) 
3.73 -0.101  
(0.118) 
0.71 -0.059  
(0.290) 
0.87 
SLC38A7 -0.297  
(1.4x10-41) 
<0.0001 -0.354  
(1.2x10-22) 
<0.0001 -0.143 
 (0.002) 
0.03 -0.578  
(8.9x10-23) 
<0.0001 -0.318  
(3.7x10-9) 
<0.0001 
SLC38A8 0.034  
(0.134) 
0.40 0.37  
(0.322) 
1.93 -0.011  
(0.812) 
0.40 -0.041  
(0.526) 
2.63 0.034  
(0.538) 
0.11 
 
  
Supplementary Table 5: Association between SLC3A2 protein expression and other biomarkers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  All cases 
 
Low, n (%) High, n (%) 
χ2 
(p-value) 
c-MYC    
Negative 341 (51.7) 318 (48.3) 20.73 
(0.000005) Positive 35 (29.2) 85 (70.8) 
Ki67    
Negative 158 (61.7) 98 (38.3) 18.28 
(0.00001) Positive 238 (45.4) 286 (54.6) 
P-mTORC1    
Negative 182 (42.6) 245 (57.4) 19.35 
(0.00001) Positive 183(59.0) 127 (41.0) 
PIK3CA    
Negative 109 (61.1) 68 (38.4) 13.67 
(0.0002) Positive 248 (45.6) 296 (54.4) 
SLC1A5    
Negative 275 (68.4) 127 (31.6) 92.92 
(5.4x10-22) Positive 201 (36.7) 346 (63.3) 
SLC7A5    
Negative 447 (61.2) 283 (38.8) 206.85 
(6.6x10-47) Positive 2 (1.1) 176 (98.9) 
GLS    
Negative 274 (58.7) 193 (41.3) 62.18 
(3.1x10-15) Positive 101 (30.4) 231 (69.6) 
Supplementary table 6: multivariate analysis of prognostic variables and SLC3A2 
expression, in relation to BCSS, in different BC subtypes. 
SLC3A2 protein 
 
ER-low proliferation ER-High proliferation 
 
Triple Negative 
 
HER2+ 
Variable Hazard ratio  
(95% CI) 
p-value 
Hazard ratio  
(95% CI) 
p-value 
Hazard ratio  
(95% CI) 
p-value 
Hazard ratio  
(95% CI) 
p-value 
SLC3A2 1.36 (0.67-2.76) 0.392 1.86 (1.11-3.12) 0.01 1.77 (1.11-2.81) 0.01 1.58 (0.94-2.69) 0.08 
Size 1.53 (0.69-3.34) 0.291 1.73 (0.97-3.07) 0.06 1.40 (0.88-2.23) 0.153 1.71 (0.99-2.94) 0.05 
Grade 1.27 (0.68-2.38) 0.449 2.55 (0.35-18.41) 0.354 2.23 (0.84-5.90) 0.107 1.75 (0.87-3.54) 0.12 
Stage 3.55 (2.15-5.88) 8.2x10-7 1.57 (1.14-2.15) 0.005 2.29 (1.73-3.05) 7.9x10-9 2.24 (1.63-3.10) 7.8x10-7 
 
  
  
 
 
Supplementary figure 1: SLC3A2 gene expression and its association, using Breast Cancer 
Gene-Expression Miner, with: A) tumour grade, B) NPI, C) ER status, D) PR status, E) HER2 
status, F) Triple Negative status, G) PAM50 subtypes. 
 
      
 
 
 
 Supplementary Figure 2. SLC3A2 protein vs DMFS in A) all cases, B) ER+- Low 
Proliferation tumours, C) ER+- High Proliferation tumours, D) HER2+ tumours, E) Triple 
negative tumours. 
 
 
 
 
 
     
 
 
 
 
  
 
 
 
Figure legends 
Figure 1: SLC3A2 expression and its association with Copy Number Aberrations, 
clinicopathological parameters and molecular subtypes: A) SLC3A2 and Gene Copy Number 
Variations, B) SLC3A2 and tumour grade, C) SLC3A2 and lymph node stage, D) SLC3A2 and 
NPI, E) SLC3A2 and PAM 50 subtypes, F) SLC3A2 and METABRIC Integrative clusters.  
Figure 2: Western blotting results for A) SLC3A2 expression in MDA-MB-231 breast cancer cell 
lysates, SLC3A2 protein expression in invasive breast cancer cores. B) Positive IHC expression, C) 
Negative IHC expression. 
Figure 3: SLC3A2 and breast cancer patient outcome. A) SLC3A2 vs BCSS in all cases, B) 
SLC3A2 vs BCSS in all cases, C) SLC3A2 vs BCSS of ER+- Low Proliferation tumours, D) 
SLC3A2 vs BCSS of ER+- High Proliferation tumours, E) SLC3A2 vs BCSS in HER2+ 
tumours, F) SLC3A2 vs BCSS in Triple Negative tumours.  
Supplementary figure 1: SLC3A2 gene expression and its association, using Breast Cancer 
Gene-Expression Miner, with: A) tumour grade, B) NPI, C) ER status, D) PR status, E) HER2 
status, F) Triple Negative status, G) PAM50 subtypes. 
Supplementary Figure 2. SLC3A2 vs DMFS in A) all cases, B) ER+- Low Proliferation 
tumours, C) ER+- High Proliferation tumours, D) HER2+ tumours, E) Triple negative tumours. 
 
